Chen CC, Silberman RE, Ma D, Perry JA, Khalid D, Pikman Y, Amon A, Hemann MT, Rowe RG. Inherent genome instability underlies trisomy 21-associated myeloid malignancies. Leukemia. 2024 Mar;38(3):521-529. doi: 10.1038/s41375-024-02151-8. Epub 2024 Jan 20. PMID: 38245602.

Miller AB, Rodriguez FH, Langenbucher A, Lin L, Bray C, Duquette S, Zhang Y, Goulet D, Lane AA, Weinstock DM, Hemann MT, Manalis SR. Leukemia circulation kinetics revealed through blood exchange method. Commun Biol. 2024 Apr 20;7(1):483. doi: 10.1038/s42003-024-06181-x. PMID: 38643279; PMCID: PMC11032325

Leylek O, Honeywell ME, Lee MJ, Hemann MT, Ozcan G. Functional genomics reveals an off-target dependency of drug synergy in gastric cancer therapy. Gastric Cancer. 2024 Nov;27(6):1201-1219. doi: 10.1007/s10120-024-01537-y. Epub 2024 Jul 20. PMID: 39033209; PMCID: PMC11513712.

Eidell KP, Hemann MT. FAS-less allogeneic CAR T cells. Nat Biomed Eng. 2024 Dec;8(12):1518-1520. doi: 10.1038/s41551-024-01319-y. PMID: 39706983.

Mofunanya A, Cameron ER, Braun CJ, Celeste F, Zhao X, Hemann MT, Scott KL, Li J, Powers S. Simultaneous screening of overexpressed genes in breast cancer for oncogenic drivers and tumor dependencies. Sci Rep. 2024 Jun 9;14(1):13227. doi: 10.1038/s41598-024-64297-w. PMID: 38851782; PMCID: PMC11162420.

Ramos A, Koch CE, Liu-Lupo Y, Hellinger RD, Kyung T, Abbott KL, Fröse J, Goulet D, Gordon KS, Eidell KP, Leclerc P, Whittaker CA, Larson RC, Muscato AJ, Yates KB, Dubrot J, Doench JG, Regev A, Vander Heiden MG, Maus MV, Manguso RT, Birnbaum ME, Hemann MT. Leukemia-intrinsic determinants of CAR-T response revealed by iterative in vivo genome-wide CRISPR screening. Nat Commun. 2023 Dec 5;14(1):8048. doi: 10.1038/s41467-023-43790-2. PMID: 38052854; PMCID: PMC10698189.

Vassel FM, Laverty DJ, Bian K, Piett CG, Hemann MT, Walker GC, Nagel ZD. REV7 Monomer Is Unable to Participate in Double Strand Break Repair and Translesion Synthesis but Suppresses Mitotic Errors. Int J Mol Sci. 2023 Oct 31;24(21):15799. doi: 10.3390/ijms242115799. PMID: 37958783; PMCID: PMC10649693.

Leylek O, Honeywell ME, Lee MJ, Hemann MT, Ozcan G. Functional genomics reveals an off-target dependency of drug synergy in gastric cancer therapy. bioRxiv [Preprint]. 2023 Nov 19:2023.10.07.561351. doi: 10.1101/2023.10.07.561351. PMID: 37873383; PMCID: PMC10592690.

Miller AB, Langenbucher A, Rodriguez FH, Lin L, Bray C, Duquette S, Zhang Y, Goulet D, Lane AA, Weinstock DM, Hemann MT, Manalis SR. Leukemia circulation kinetics revealed through blood exchange method. bioRxiv [Preprint]. 2023 Sep 5:2023.09.03.556043. doi: 10.1101/2023.09.03.556043. PMID: 37732189; PMCID: PMC10508764.

Liu-Lupo Y, Ham JD, Jeewajee SKA, Nguyen L, Delorey T, Ramos A, Weinstock DM, Regev A, Hemann MT. Integrated multi-omics analyses reveal homology-directed repair pathway as a unique dependency in near-haploid leukemia. Blood Cancer J. 2023 Jun 8;13(1):92. doi: 10.1038/s41408-023-00863-1. PMID: 37286545; PMCID: PMC10247733.

Gordon KS, Kyung T, Perez CR, Holec PV, Ramos A, Zhang AQ, Agarwal Y, Liu Y, Koch CE, Starchenko A, Joughin BA, Lauffenburger DA, Irvine DJ, Hemann MT, Birnbaum ME. Author Correction: Screening for CD19-specific chimaeric antigen receptors with enhanced signalling via a barcoded library of intracellular domains. Nat Biomed Eng. 2023 Apr;7(4):599-602. doi: 10.1038/s41551-023-01006-4. Erratum for: Nat Biomed Eng. 2022 Jul;6(7):855-866. PMID: 36737667.

Gordon KS, Kyung T, Perez CR, Holec PV, Ramos A, Zhang AQ, Agarwal Y, Liu Y, Koch CE, Starchenko A, Joughin BA, Lauffenburger DA, Irvine DJ, Hemann MT, Birnbaum ME. Screening for CD19-specific chimaeric antigen receptors with enhanced signalling via a barcoded library of intracellular domains. Nat Biomed Eng. 2022 Jul;6(7):855-866. doi: 10.1038/s41551-022-00896-0. Epub 2022 Jun 16. Erratum in: Nat Biomed Eng. 2023 Apr;7(4):599-602. PMID: 35710755; PMCID: PMC9389442.

Dalin S, Grauman-Boss B, Lauffenburger DA, Hemann MT. Collateral responses to classical cytotoxic chemotherapies are heterogeneous and sensitivities are sparse. Sci Rep. 2022 Mar 31;12(1):5453. doi: 10.1038/s41598-022-09319-1. PMID: 35361803; PMCID: PMC8971507.

Bent EH, Millán-Barea LR, Zhuang I, Goulet DR, Fröse J, Hemann MT. Microenvironmental IL-6 inhibits anti-cancer immune responses generated by cytotoxic chemotherapy. Nat Commun. 2021 Oct 28;12(1):6218. doi: 10.1038/s41467-021-26407-4. PMID: 34711820; PMCID: PMC8553783.

Mueller HS, Fowler CE, Dalin S, Moiso E, Udomlumleart T, Garg S, Hemann MT, Lees JA. Acquired resistance to PRMT5 inhibition induces concomitant collateral sensitivity to paclitaxel. Proc Natl Acad Sci U S A. 2021 Aug 24;118(34):e2024055118. doi: 10.1073/pnas.2024055118. PMID: 34408017; PMCID: PMC8403834.

Sánchez-Rivera FJ, Ryan J, Soto-Feliciano YM, Clare Beytagh M, Xuan L, Feldser DM, Hemann MT, Zamudio J, Dimitrova N, Letai A, Jacks T. Mitochondrial apoptotic priming is a key determinant of cell fate upon p53 restoration. Proc Natl Acad Sci U S A. 2021 Jun 8;118(23):e2019740118. doi: 10.1073/pnas.2019740118. PMID: 34074758; PMCID: PMC8201929.

Roux B, Vaganay C, Vargas JD, Alexe G, Benaksas C, Pardieu B, Fenouille N, Ellegast JM, Malolepsza E, Ling F, Sodaro G, Ross L, Pikman Y, Conway AS, Tang Y, Wu T, Anderson DJ, Le Moigne R, Zhou HJ, Luciano F, Hartigan CR, Galinsky I, DeAngelo DJ, Stone RM, Auberger P, Schenone M, Carr SA, Guirouilh-Barbat J, Lopez B, Khaled M, Lage K, Hermine O, Hemann MT, Puissant A, Stegmaier K, Benajiba L. Targeting acute myeloid leukemia dependency on VCP-mediated DNA repair through a selective second-generation small-molecule inhibitor. Sci Transl Med. 2021 Mar 31;13(587):eabg1168. doi: 10.1126/scitranslmed.abg1168. PMID: 33790022; PMCID: PMC8672851.

Dowling CM, Hollinshead KER, Di Grande A, Pritchard J, Zhang H, Dillon ET, Haley K, Papadopoulos E, Mehta AK, Bleach R, Lindner AU, Mooney B, Düssmann H, O'Connor D, Prehn JHM, Wynne K, Hemann M, Bradner JE, Kimmelman AC, Guerriero JL, Cagney G, Wong KK, Letai AG, Chonghaile TN. Multiple screening approaches reveal HDAC6 as a novel regulator of glycolytic metabolism in triple-negative breast cancer. Sci Adv. 2021 Jan 15;7(3):eabc4897. doi: 10.1126/sciadv.abc4897. PMID: 33523897; PMCID: PMC7810372.

Jiang T, Sánchez-Rivera FJ, Soto-Feliciano YM, Yang Q, Song CQ, Bhuatkar A, Haynes CM, Hemann MT, Xue W. Targeting the De Novo Purine Synthesis Pathway Through Adenylosuccinate Lyase Depletion Impairs Liver Cancer Growth by Perturbing Mitochondrial Function. Hepatology. 2021 Jul;74(1):233-247. doi: 10.1002/hep.31685. Epub 2021 Jul 12. PMID: 33336367; PMCID: PMC8209110.

Chatterjee N, Whitman MA, Harris CA, Min SM, Jonas O, Lien EC, Luengo A, Vander Heiden MG, Hong J, Zhou P, Hemann MT, Walker GC. REV1 inhibitor JH-RE-06 enhances tumor cell response to chemotherapy by triggering senescence hallmarks. Proc Natl Acad Sci U S A. 2020 Nov 17;117(46):28918-28921. doi: 10.1073/pnas.2016064117. Epub 2020 Nov 9. PMID: 33168727; PMCID: PMC7682577.

Vassel FM, Bian K, Walker GC, Hemann MT. Rev7 loss alters cisplatin response and increases drug efficacy in chemotherapy-resistant lung cancer. Proc Natl Acad Sci U S A. 2020 Nov 17;117(46):28922-28924. doi: 10.1073/pnas.2016067117. Epub 2020 Nov 3. PMID: 33144509; PMCID: PMC7682549.

Layer JV, Debaize L, Van Scoyk A, House NC, Brown AJ, Liu Y, Stevenson KE, Hemann M, Roberts SA, Price BD, Weinstock DM, Day TA. Polymerase δ promotes chromosomal rearrangements and imprecise double-strand break repair. Proc Natl Acad Sci U S A. 2020 Nov 3;117(44):27566-27577. doi: 10.1073/pnas.2014176117. Epub 2020 Oct 19. PMID: 33077594; PMCID: PMC7959522.

Liu Y, Shi N, Regev A, He S, Hemann MT. Integrated regulatory models for inference of subtype-specific susceptibilities in glioblastoma. Mol Syst Biol. 2020 Sep;16(9):e9506. doi: 10.15252/msb.20209506. PMID: 32974985; PMCID: PMC7516378.

Kong YW, Dreaden EC, Morandell S, Zhou W, Dhara SS, Sriram G, Lam FC, Patterson JC, Quadir M, Dinh A, Shopsowitz KE, Varmeh S, Yilmaz ÖH, Lippard SJ, Reinhardt HC, Hemann MT, Hammond PT, Yaffe MB. Enhancing chemotherapy response through augmented synthetic lethality by co-targeting nucleotide excision repair and cell-cycle checkpoints. Nat Commun. 2020 Aug 17;11(1):4124. doi: 10.1038/s41467-020-17958-z. PMID: 32807787; PMCID: PMC7431578.

Qi R, Wang Y, Bruno PM, Xiao H, Yu Y, Li T, Lauffer S, Wei W, Chen Q, Kang X, Song H, Yang X, Huang X, Detappe A, Matulonis U, Pepin D, Hemann MT, Birrer MJ, Ghoroghchian PP. Author Correction: Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer. Nat Commun. 2020 Apr 17;11(1):1940. doi: 10.1038/s41467-020-14903-y. Erratum for: Nat Commun. 2017 Dec 18;8(1):2166. PMID: 32303677; PMCID: PMC7165165.

Bruno PM, Lu M, Dennis KA, Inam H, Moore CJ, Sheehe J, Elledge SJ, Hemann MT, Pritchard JR. The primary mechanism of cytotoxicity of the chemotherapeutic agent CX-5461 is topoisomerase II poisoning. Proc Natl Acad Sci U S A. 2020 Feb 25;117(8):4053-4060. doi: 10.1073/pnas.1921649117. Epub 2020 Feb 10. PMID: 32041867; PMCID: PMC7049172.

Dalin S, Sullivan MR, Lau AN, Grauman-Boss B, Mueller HS, Kreidl E, Fenoglio S, Luengo A, Lees JA, Vander Heiden MG, Lauffenburger DA, Hemann MT. Deoxycytidine Release from Pancreatic Stellate Cells Promotes Gemcitabine Resistance. Cancer Res. 2019 Nov 15;79(22):5723-5733. doi: 10.1158/0008-5472.CAN-19-0960. Epub 2019 Sep 4. PMID: 31484670; PMCID: PMC7357734.

Liu Y, Hemann MT. A dynamic view of chemotherapy effectiveness. Nature. 2019 Aug;572(7769):321-322. doi: 10.1038/d41586-019-02336-7. PMID: 31406309.

Wojtaszek JL, Chatterjee N, Najeeb J, Ramos A, Lee M, Bian K, Xue JY, Fenton BA, Park H, Li D, Hemann MT, Hong J, Walker GC, Zhou P. A Small Molecule Targeting Mutagenic Translesion Synthesis Improves Chemotherapy. Cell. 2019 Jun 27;178(1):152-159.e11. doi: 10.1016/j.cell.2019.05.028. Epub 2019 Jun 6. PMID: 31178121; PMCID: PMC6644000.

Braun CJ, Hemann MT. Functional screens identify coordinators of RNA molecule birth, life, and death as targetable cancer vulnerabilities. Curr Opin Genet Dev. 2019 Feb;54:105-109. doi: 10.1016/j.gde.2019.04.003. Epub 2019 May 20. PMID: 31121413.

Lossos C, Liu Y, Kolb KE, Christie AL, Van Scoyk A, Prakadan SM, Shigemori K, Stevenson KE, Morrow S, Plana OD, Fraser C, Jones KL, Liu H, Pallasch CP, Modiste R, Nguyen QD, Craig JW, Morgan EA, Vega F, Aster JC, Sarosiek KA, Shalek AK, Hemann MT, Weinstock DM. Mechanisms of Lymphoma Clearance Induced by High-Dose Alkylating Agents. Cancer Discov. 2019 Jul;9(7):944-961. doi: 10.1158/2159-8290.CD-18-1393. Epub 2019 Apr 30. PMID: 31040105; PMCID: PMC6606344.

Benajiba L, Alexe G, Su A, Raffoux E, Soulier J, Hemann MT, Hermine O, Itzykson R, Stegmaier K, Puissant A. Creatine kinase pathway inhibition alters GSK3 and WNT signaling in EVI1-positive AML. Leukemia. 2019 Mar;33(3):800-804. doi: 10.1038/s41375-018-0291-x. Epub 2018 Nov 2. PMID: 30390009; PMCID: PMC6596421.

Rizzo AA, Vassel FM, Chatterjee N, D'Souza S, Li Y, Hao B, Hemann MT, Walker GC, Korzhnev DM. Rev7 dimerization is important for assembly and function of the Rev1/Polζ translesion synthesis complex. Proc Natl Acad Sci U S A. 2018 Aug 28;115(35):E8191-E8200. doi: 10.1073/pnas.1801149115. Epub 2018 Aug 15. PMID: 30111544; PMCID: PMC6126741.

Fiedler ERC, Bhutkar A, Lawler E, Besada R, Hemann MT. In vivo RNAi screening identifies Pafah1b3 as a target for combination therapy with TKIs in BCR-ABL1+ BCP-ALL. Blood Adv. 2018 Jun 12;2(11):1229-1242. doi: 10.1182/bloodadvances.2017015610. PMID: 29853524; PMCID: PMC5998924.

Kauke MJ, Tisdale AW, Kelly RL, Braun CJ, Hemann MT, Wittrup KD. A Raf-Competitive K-Ras Binder Can Fail to Functionally Antagonize Signaling. Mol Cancer Ther. 2018 Aug;17(8):1773-1780. doi: 10.1158/1535-7163.MCT-17-0645. Epub 2018 May 2. PMID: 29720559.

Wagner FF, Benajiba L, Campbell AJ, Weïwer M, Sacher JR, Gale JP, Ross L, Puissant A, Alexe G, Conway A, Back M, Pikman Y, Galinsky I, DeAngelo DJ, Stone RM, Kaya T, Shi X, Robers MB, Machleidt T, Wilkinson J, Hermine O, Kung A, Stein AJ, Lakshminarasimhan D, Hemann MT, Scolnick E, Zhang YL, Pan JQ, Stegmaier K, Holson EB. Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. Sci Transl Med. 2018 Mar 7;10(431):eaam8460. doi: 10.1126/scitranslmed.aam8460. PMID: 29515000; PMCID: PMC6553635.

Qi R, Wang Y, Bruno PM, Xiao H, Yingjie Y, Li T, Lauffer S, Wei W, Chen Q, Kang X, Song H, Yang X, Huang X, Detappe A, Matulonis U, Pepin D, Hemann MT, Birrer MJ, Ghoroghchian PP. Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer. Nat Commun. 2017 Dec 18;8(1):2166.

Braun CJ, Stanciu M, Boutz PL, Patterson JC, Calligaris D, Higuchi F, Neupane R, Fenoglio S, Cahill DP, Wakimoto H, Agar NYR, Yaffe MB, Sharp PA, Hemann MT, Lees JA. Coordinated Splicing of Regulatory Detained Introns within Oncogenic Transcripts Creates an Exploitable Vulnerability in Malignant Glioma. Cancer Cell. 2017 Oct 9;32(4):411-426. PMCID: In Process

Tang YC, Yuwen H, Wang K, Bruno PM, Bullock K, Deik A, Santaguida S, Trakala M, Pfau SJ, Zhong N, Huang T, Wang L, Clish CB, Hemann MT, Amon A. Aneuploid Cell Survival Relies upon Sphingolipid Homeostasis. Cancer Res. 2017 Oct 1;77(19):5272-5286. PMCID: PMC5772763

Yamanaka K, Chatterjee N, Hemann MT, Walker GC. Inhibition of mutagenic translesion synthesis: A possible strategy for improving chemotherapy? PLoS Genet. 2017 Aug 17;13(8):e1006842. PMCID: PMC5560539

Ramos A, Hemann MT. Drugs, Bugs, and Cancer: Fusobacterium nucleatum Promotes Chemoresistance in Colorectal Cancer. Cell. 2017 Jul 27;170(3):411-413.

Miller TE, Liau BB, Wallace LC, Morton AR, Xie Q, Dixit D, Factor DC, Kim LJY, Morrow JJ, Wu Q, Mack SC, Hubert CG, Gillespie SM, Flavahan WA, Hoffmann T, Thummalapalli R, Hemann MT, Paddison PJ, Horbinski CM, Zuber J, Scacheri PC, Bernstein BE, Tesar PJ, Rich JN. Transcription elongation factors represent in vivo cancer dependencies in glioblastoma. Nature. 2017 Jul 20;547(7663):355-359. PMCID: In Process

*Flamme M, Cressey PB, Lu C, Bruno PM, Eskandari A, Hemann MT, Hogarth G, Suntharalingam K. Induction of Necroptosis in Cancer Stem Cells using a Nickel(II)-Dithiocarbamate Phenanthroline Complex. Chemistry. 2017 May 26. PMCID: In Process

*Soto-Feliciano YM, Bartlebaugh JME, Liu Y, Sánchez-Rivera FJ, Bhutkar A, Weintraub AS, Buenrostro JD, Cheng CS, Regev A, Jacks TE, Young RA, Hemann MT. PHF6 regulates phenotypic plasticity through chromatin organization within lineage-specific genes. Genes Dev. 2017 May 15;31(10):973-989. PMCID: PMC5495126

*Bruno PM, Liu Y, Park GY, Murai J, Koch CE, Eisen TJ, Pritchard JR, Pommier Y, Lippard SJ, Hemann MT. A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. Nat Med. 2017 Apr;23(4):461-471. PMCID: PMC5520548

*Fenouille N, Bassil CF, Ben-Sahra I, Benajiba L, Alexe G, Ramos A, Pikman Y, Conway AS, Burgess MR, Li Q, Luciano F, Auberger P, Galinsky I, DeAngelo DJ, Stone RM, Zhang Y, Perkins AS, Shannon K, Hemann MT, Puissant A, Stegmaier K. The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia. Nat Med. 2017 Mar;23(3):301-313. PMCID: PMC5540325

* papers arising from a supervised thesis

*Eskandari A, Boodram JN, Cressey PB, Lu C, Bruno PM, Hemann MT, Suntharalingam K. The breast cancer stem cell potency of copper(ii) complexes bearing nonsteroidal anti-inflammatory drugs and their encapsulation using polymeric nanoparticles. Dalton Trans. 2016 Nov 28;45(44):17867-17873. PMCID: In Process

*Sun D, Dalin S, Hemann MT, Lauffenburger DA, Zhao B. Differential selective pressure alters rate of drug resistance acquisition in heterogeneous tumor populations. Sci Rep. 2016 Nov 7;6:36198. PMCID: PMC5098152

*Zheng YR, Suntharalingam K, Bruno PM, Lin W, Wang W, Hemann MT, Lippard SJ. Mechanistic Studies of the Anticancer Activity of An Octahedral Hexanuclear Pt(II) Cage. Inorganica Chim Acta. 2016 Oct 1;452:125-129. PMCID: PMC5094802

*Lindblad O, Cordero E, Puissant A, Macaulay L, Ramos A, Kabir NN, Sun J, Vallon-Christersson J, Haraldsson K, Hemann MT, Borg Å, Levander F, Stegmaier K, Pietras K, Rönnstrand L, Kazi JU. Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML. PMCID: PMC5399143

*Barnes JC, Bruno PM, Nguyen HV, Liao L, Liu J, Hemann MT, Johnson JA. Using an RNAi Signature Assay To Guide the Design of Three-Drug-Conjugated Nanoparticles with Validated Mechanisms, In Vivo Efficacy, and Low Toxicity. J Am Chem Soc. 2016 Sep 28;138(38):12494-501. PMCID: PMC5597434

*Cressey PB, Eskandari A, Bruno PM, Lu C, Hemann MT, Suntharalingam K. The Potent Inhibitory Effect of a Naproxen-Appended Cobalt(III)-Cyclam Complex on Cancer Stem Cells. Chembiochem. 2016 Sep 15;17(18):1713-8. PMCID: In Process

Braun CJ, Hemann MT. Rewiring the solid tumor epigenome for cancer therapy. Expert Rev Anticancer Ther. 2016 Sep;16(9):977-87.

*Bent EH, Gilbert LA, Hemann MT. A senescence secretory switch mediated by PI3K/AKT/mTOR activation controls chemoprotective endothelial secretory responses. Genes Dev. 2016 Aug 15;30(16):1811-21. PMCID: PMC5024680

*Braun CJ, Bruno PM, Horlbeck MA, Gilbert LA, Weissman JS, Hemann MT. Versatile in vivo regulation of tumor phenotypes by dCas9-mediated transcriptional perturbation. Proc Natl Acad Sci U S A. 2016 Jul 5;113(27):E3892-900. PMCID: PMC4941480

*Pikman Y, Puissant A, Alexe G, Furman A, Chen LM, Frumm SM, Ross L, Fenouille N, Bassil CF, Lewis CA, Ramos A, Gould J, Stone RM, DeAngelo DJ, Galinsky I, Clish CB, Kung AL, Hemann MT, Vander Heiden MG, Banerji V, Stegmaier K. Targeting MTHFD2 in acute myeloid leukemia. J Exp Med. 2016 Jun 27;213(7):1285-306. PMCID: PMC4925018

*Zhao B, Sedlak JC, Srinivas R, Creixell P, Pritchard JR, Tidor B, Lauffenburger DA, Hemann MT. Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution. Cell. 2016 Mar 24;165(1):234-46. PMCID: PMC5152932

*Boodram JN, Mcgregor IJ, Bruno PM, Cressey PB, Hemann MT, Suntharalingam K. Breast Cancer Stem Cell Potent Copper(II)-Non-Steroidal Anti-Inflammatory Drug Complexes. Angew Chem Int Ed Engl. 2016 Feb 18;55(8):2845-50. PMCID: In Process

* papers arising from a supervised thesis

*Awuah SG, Zheng YR, Bruno PM, Hemann MT, Lippard SJ. A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy. J Am Chem Soc. 2015 Dec 2;137(47):14854-7. PMCID: PMC4772771

*Cannell IG, Merrick KA, Morandell S, Zhu CQ, Braun CJ, Grant RA, Cameron ER, Tsao MS, Hemann MT, Yaffe MB. A Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to Drive Resistance of p53-Defective Tumors to Chemotherapy. Cancer Cell. 2015 Oct 20. PMCID: PMC4830093

McFaline-Figueroa JL, Braun CJ, Stanciu M, Nagel ZD, Mazzucato P, Sangaraju D, Cerniauskas E, Barford K, Vargas A, Chen Y, Tretyakova N, Lees JA, Hemann MT, White FM, Samson LD. Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide. Cancer Res. 2015 Aug 1;75(15):3127-38. PMCID: PMC4526337

Hemann M. Syngeneic Transplants with Modified Chimeric Hematopoietic Tumors. Cold Spring Harb Protoc. 2015 Aug 3;2015(8):735-9.

Hemann M. Loss-of-Function Screening in Hematopoietic Malignancies. Cold Spring Harb Protoc. 2015 Aug 3;2015(8):740-2.

Hemann M. Chimeric Tumor and Organ Transplantation Models. Cold Spring Harb Protoc. 2015 Aug 3;2015(8):725-30.

Zender L, Hemann M. Reconstitution of Mice with Modified Liver Stem Cells. Cold Spring Harb Protoc. 2015 Jul 1;2015(7):685-8.

Hemann M. Reconstitution of Mice with Modified Hematopoietic Stem Cells. Cold Spring Harb Protoc. 2015 Jul 1;2015(7):679-84.

Liu C, Ding H, Li X, Pallasch CP, Hong L, Guo D, Chen Y, Wang D, Wang W, Wang Y, Hemann MT, Jiang H. A DNA/HDAC dual-targeting drug CY190602 with significantly enhanced anticancer potency. EMBO Mol Med. 2015 Mar 9. PMCID: PMC4403045

*Suntharalingam K, Awuah SG, Bruno PM, Johnstone TC, Wang F, Lin W, Zheng YR, Page JE, Hemann MT, Lippard SJ. Necroptosis-inducing rhenium(v) oxo complexes. J Am Chem Soc. 2015 Mar 4;137(8):2967-74. PMCID: PMC4702498

*Meacham CE, Lawton LN, Soto-Feliciano YM, Pritchard JR, Joughin BA, Ehrenberger T, Fenouille N, Zuber J, Williams RT, Young RA, Hemann MT. A genome-scale in vivo loss-of-function screen identifies Phf6 as a lineage-specific regulator of leukemia cell growth. Genes Dev. 2015 Mar 1;29(5):483-8. PMCID: PMC4358400

*Shingleton JR, Hemann MT. The Chromatin Regulator CHD8 Is a Context-Dependent Mediator of Cell Survival in Murine Hematopoietic Malignancies. PLoS One. 2015 Nov 20;10(11). PMCID: PMC4654476

* papers arising from a supervised thesis

*Suntharalingam K, Lin W, Johnstone TC, Bruno PM, Zheng YR, Hemann MT, Lippard SJ. A breast cancer stem cell-selective, mammospheres-potent osmium(VI) nitrido complex. J Am Chem Soc. 2014 Oct 15;136(41):14413-6. PMCID: PMC4210142

*Zhao B, Hemann MT, Lauffenburger DA. Reply to Azuaje: Predicting effective combined therapies for heterogeneous tumors. Proc Natl Acad Sci U S A. 2014 Oct 14;111(41):E4288. PMCID: PMC4205616

*Zhao B, Hemann MT, Lauffenburger DA. Intratumor heterogeneity alters most effective drugs in designed combinations. Proc Natl Acad Sci U S A. 2014 Jul 22;111(29): 10773-8. PMCID: PMC4115561

Hemann MT. From breaking bad to worse: exploiting homologous DNA repair deficiency in cancer. Cancer Discov. 2014 May;4(5):516-8. PMCID: PMC4384127

Puissant A, Fenouille N, Alexe G, Pikman Y, Bassil CF, Mehta S, Du J, Kazi JU, Luciano F, Rönnstrand L, Kung AL, Aster JC, Galinsky I, Stone RM, Deangelo DJ, Hemann MT, Stegmaier K. SYK Is a Critical Regulator of FLT3 in Acute Myeloid Leukemia. Cancer Cell. 2014 Feb 10;25(2): 226-42. PMCID: PMC4106711

*Zhao B, Pritchard JR, Lauffenburger DA, Hemann MT. Addressing genetic tumor heterogeneity through computationally predictive combination therapy. Cancer Discov. 2014 Feb;4(2):166-74. PMCID: PMC3975231

*Pallasch C, Leskov I, Braun C, Vorholt D, Drake A, Soto-Feliciano Y, Bent E, Schwamb J, Iliopoulou B, Kutsch N, van Rooijen N, Frenzel L, Wendtner C, Heukamp L, Kreuzer K, Hallek M, Chen J, Hemann M. Sensitizing Protective Tumor Microenvironments to Antibody-Mediated Therapy. Cell. 2014 Jan 30;156(3):590-602. PMCID: PMC3975171

* papers arising from a supervised thesis

*Suntharalingam K, Johnstone TC, Bruno PM, Lin W, Hemann MT, Lippard SJ. Bidentate ligands on osmium(VI) nitrido complexes control intracellular targeting and cell death pathways. J Am Chem Soc. 2013 Sep 25;135(38):14060-3. PMCID: PMC3791136

Wilson JL, Hemann MT, Fraenkel E, Lauffenburger DA. Integrated network analyses for functional genomic studies in cancer. Semin Cancer Biol. 2013 Aug;23(4):213-8. PMCID: PMC3844556

*Pritchard JR, Bruno PM, Hemann MT, Lauffenburger DA. Predicting cancer drug mechanisms of action using molecular network signatures. Mol Biosyst. 2013 Jul;9(7):1604-19. PMCID: PMC3945388

Braun CJ, Hemann MT. Unraveling tumor suppressor networks with in vivo RNAi. Cell Stem Cell. 2013 Jun 6;12(6):639-41.

Pavlova NN, Pallasch C, Elia AE, Braun CJ, Westbrook TF, Hemann M, Elledge SJ. A role for PVRL4-driven cell-cell interactions in tumorigenesis. Elife. 2013 Apr 30;2:e00358. PMCID: PMC3641523

Leskov I, Pallasch CP, Drake A, Iliopoulou BP, Souza A, Shen CH, Schweighofer CD, Abruzzo L, Frenzel LP, Wendtner CM, Hemann MT, Chen J. Rapid generation of human B-cell lymphomas via combined expression of Myc and Bcl2 and their use as a preclinical model for biological therapies. Oncogene. 2013 Feb 21;32(8):1066-72. PMCID: PMC4117216

*Pritchard JR, Bruno PM, Gilbert LA, Capron KL, Lauffenburger DA, Hemann MT. Defining principles of combination drug mechanisms of action. Proc Natl Acad Sci U S A. 2013 Jan 8;110(2):E170-9. PMCID: PMC3545813

* papers arising from a supervised thesis

*Pritchard JR, Lauffenburger DA, Hemann MT. Understanding resistance to combination chemotherapy. Drug Resist Updat. 2012 Oct;15(5-6):249-57. PMCID: PMC3975170

*Gilbert LA, Hemann MT. Context-specific roles for paracrine IL-6 in lymphomagenesis. Genes Dev. 2012 Aug 1;26(15):1758-68. PMCID: PMC3418592

*Pritchard JR, Gilbert LA, Meacham CE, Ricks JL, Jiang H, Lauffenburger DA, Hemann MT. (2011). Bcl-2 family genetic profiling reveals microenvironment-specific determinants of chemotherapeutic response. Cancer Res., 71(17), 5850-5858. PMCID: PMC3165087

* papers arising from a supervised thesis

Gilbert LA, Hemann MT. (2011). Chemotherapeutic resistance: surviving stressful situations. Cancer Res., 71(15), 5062-5066. PMCID: PMC3148403

Stadanlick JE, Zhang Z, Lee SY, Hemann M, Biery M, Carleton MO, Zambetti GP, Anderson SJ, Oravecz T, Wiest DL. (2011). Developmental arrest of T cells in Rpl22-deficient mice is dependent upon multiple p53 effectors. J Immunol., 187(2), 664-675. PMCID: PMC3131471

*Jiang H, Pritchard JR, Williams RT, Lauffenburger DA, Hemann MT. (2011) A mammalian functional-genetic approach to characterizing cancer therapeutics. Nat. Chem. Biol., 7(2), 92-100. PMCID: PMC3070540

* papers arising from a supervised thesis

*Xie K, Doles J, Hemann MT, Walker GC. (2010) Error-prone translesion synthesis mediates acquired chemoresistance. Proc. Natl. Acad. Sci. USA, 107(48), 20792-20797. PMCID: PMC2996453

*Doles J, Oliver TG, Cameron ER, Hsu G, Jacks T, Walker GC, Hemann MT. (2010) Suppression of Rev3, the catalytic subunit of Pol{zeta}, sensitizes drug-resistant lung tumors to chemotherapy. Proc. Natl. Acad. Sci. USA, 107(48), 20786-20791. PMCID: PMC2996428

Feldser DM, Kostova KK, Winslow MM, Taylor SE, Cashman C, Whittaker CA, Sanchez-Rivera FJ, Resnick R, Bronson R, Hemann MT, Jacks T. (2010). Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature., 468(7323), 572-557. PMCID: PMC3003305

*Gilbert LA, Hemann MT. (2010) DNA damage-mediated induction of a chemoresistant niche. Cell, 143(3), 355-366. PMCID: PMC2972353

*Doles J and Hemann MT. NEK4 status affects differential sensitivity to microtubule poisons. Cancer Res. 2010 Feb 1;70(3):1033-41. PMCID: PMC2946156

Bric A, Miething C, Bialucha CU, Scuoppo C, Zender L, Krasnitz A, Xuan Z, Zuber J, Wigler M, Hicks J, McCombie RW, Hemann MT, Hannon GJ, Powers S, Lowe SW. (2009) Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell. Oct 6;16(4):324-35. PMCID: PMC2829755

Reinhardt HC, Jiang H, Hemann MT, Yaffe MB. (2009). Exploiting synthetic lethal interactions for targeted cancer therapy. Cell Cycle., 8(19), 3112-3119. PMCID: PMC3057180

*Meacham CE, Ho E, Dubrovsky E, Gertler FB and Hemann MT. In Vivo RNAi screening identifies regulators of actin dynamics as key determinants of lymphoma progression. Nature Genetics, (2009) Oct;41(10): 1133-1137. PMCID: PMC2756700

Jiang H, Reinhardt HC, Bartkova J, Tommiska J, Blomqvist C, Nevanlinna H, Bartek J, Yaffe MB and Hemann MT. The combined status of ATM and p53 link tumor development with therapeutic response. Genes & Development, (2009) Aug 15;23(16) 1895-1909. PMCID: PMC2725944

*Pritchard JR, Cosgrove BD, Hemann MT, Griffith LG, Wands JR, Lauffenburger DA. (2009). Three-kinase inhibitor combination recreates multipathway effects of a geldanamycin analogue on hepatocellular carcinoma cell death. Mol Cancer Ther., 8(8), 2183-2192. PMCID: PMC2779718

Burgess, D.J., Doles, J., Zender, L., Xue, W., Ma, B., McCombie, W.R., Hannon, G.J., Lowe, S.W., Hemann, M.T. (2008). Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proc Natl Acad Sci, 105(26), 9053-9058. PMCID: PMC2435590.

Mayr, C., Hemann, M.T., Bartel, D. (2007). Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science, 315(5818), 1576-1579.

Hemann, M.T. and Narita, M. (2007). Oncogenes and senescence: breaking down in the fast lane. Genes Dev, 21(1), 1-5.

Hemann, M.T. and Lowe, S.W. (2006). The p53-Bcl-2 connection. Cell Death Differ, 13(8), 1256-1259

Dickins, R., Hemann, M.T., Zilfou, J., Simpson, D., Ibarra, I., Hannon, G., Lowe, S.W. (2005). Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat Genet, 37(11), 1289-1295.

Hemann, M.T., Bric, A., Teruya-Feldstein, J., Herbst, A., Nilsson, J., Cordon-Cardo, C., Cleveland, J., Tansey, W., Lowe, S.W. (2005). Evasion of the p53 tumor surveillance network by tumor-derived MYC mutants. Nature, 436(7052), 807-811.

He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ, Hammond SM. (2005). A microRNA polycistron as a potential human oncogene. Nature., 435(7043), 828-833.

Herbst A, Hemann MT, Tworkowski KA, Salghetti SE, Lowe SW, Tansey WP. (2005). A conserved element in Myc that negatively regulates its proapoptotic activity. EMBO Rep., 6(2), 177-183.

Hernando E, Nahlé Z, Juan G, Diaz-Rodriguez E, Alaminos M, Hemann M, Michel L, Mittal V, Gerald W, Benezra R, Lowe SW, Cordon-Cardo C. (2004). Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature., 430(7001), 797-802.

Chiang YJ, Hemann MT, Hathcock KS, Tessarollo L, Feigenbaum L, Hahn WC, Hodes RJ. (2004). Expression of telomerase RNA template, but not telomerase reverse transcriptase, is limiting for telomere length maintenance in vivo. Mol Cell Biol., 24(16), 7024-7031.

Hemann, M.T., Zilfou, J., Zhao, Z., Burgess, D., Hannon, G., Lowe, S. (2004). Suppression of tumorigenesis by the p53 target PUMA. Proc Natl Acad Sci, 101(25), 9333-9338.

Rabinowicz PD, Palmer LE, May BP, Hemann MT, Lowe SW, McCombie WR, Martienssen RA. (2003). Genes and transposons are differentially methylated in plants, but not in mammals. Genome Res., 13(12), 2658-2664.

O'Hearn SF, Huang CE, Hemann M, Zhelonkina A, Sollner-Webb B. (2003). Trypanosoma brucei RNA editing complex: band II is structurally critical and maintains band V ligase, which is nonessential. Mol Cell Biol., 23(21), 7909-7919.

Fridman JS, Hernando E, Hemann MT, de Stanchina E, Cordon-Cardo C, Lowe SW. (2003). Tumor promotion by Mdm2 splice variants unable to bind p53. Cancer Res., 63(18), 5703-5706.

Hemann, MT, Fridman, J, Zilfou, J, Hernando, E, Paddison, P, Cordon-Cardo, C, Hannon, G, Lowe, S (2003). An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat Genet, 33(3), 396-400.

Hemann, MT, Hathcock, K, Opperman, K, Strong, M, Greider, C, Hodes, R (2002). Haploinsufficiency of mTR results in defects in telomere elongation. Proc Natl Acad Sci, 99(6), 3591-3596.

Hemann MT, Strong MA, Hao LY, Greider CW. (2001). The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. Cell., 107(1), 67-77.

Hemann, MT, Rudolph, K, Strong, M, DePinho, R, Chin, L, Greider, C (2001). Telomere dysfunction triggers developmentally regulated germ cell apoptosis. Mol Biol of the Cell, 12, 2023-2030.

Rusché LN, Huang CE, Piller KJ, Hemann M, Wirtz E, Sollner-Webb B. (2001). The two RNA ligases of the Trypanosoma brucei RNA editing complex: cloning the essential band IV gene and identifying the band V gene. Mol Cell Biol., 21(4), 979-989.

Hemann MT, Greider CW. (2000). Wild-derived inbred mouse strains have short telomeres. Nucleic Acids Res., 28(22), 4474-4478.

Hemann MT, Hackett J, IJpma A, Greider CW. (2000). Telomere length, telomere-binding proteins, and DNA damage signaling. Cold Spring Harb Symp Quant Biol., 65, 275-279.

Hemann MT, Greider CW. (1999). G-strand overhangs on telomeres in telomerase-deficient mouse cells. Nucleic Acids Res., 27(20), 3964-3969.

Wagstaff J, Hemann M. (1995). A familial "balanced" 3;9 translocation with cryptic 8q insertion leading to deletion and duplication of 9p23 loci in siblings. Am J Hum Genet., 56(1), 302-309.

* papers arising from a supervised thesis